Metastatic Ovarian Adenocarcinoma in a Dog Treated with Ovariohysterectomy and Intracavitary Chemotherapy

2007 ◽  
Vol 38 (3/4) ◽  
pp. 63-68
Author(s):  
Teruo ITOH ◽  
Kazuyuki UCHIDA ◽  
Atsuko KOJIMOTO ◽  
Ayako IKEDA ◽  
Kazumi NIBE ◽  
...  
Keyword(s):  
Ovarian Adenocarcinoma ◽  
Intracavitary Chemotherapy

scholarly journals Pt(II)-Thiocarbohydrazone Complex as Cytotoxic Agent and Apoptosis Inducer in Caov-3 and HT-29 Cells through the P53 and Caspase-8 Pathways

2021 ◽  
Vol 14 (6) ◽  
pp. 509
Author(s):  
Abeer A. Ibrahim ◽  
Mohanad M. Kareem ◽  
Taghreed H. Al-Noor ◽  
Tahani Al-Muhimeed ◽  
Abeer A. AlObaid ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Immunofluorescence Assay ◽  
Cell Cycle Distribution ◽  
Caspase 8 ◽  
Ovarian Adenocarcinoma ◽  
Fragmentation Test ◽  
Cycle Arrest ◽  
Apoptosis Inducer ◽  
Test Flow ◽  
Ht 29

In this study, a platinum(II) complex ([Pt(H2L)(PPh3)] complex) containing a thiocarbohydrazone as the ligand was tested as an anti-proliferative agent against ovarian adenocarcinoma (Caov-3) and human colorectal adenocarcinoma (HT-29) through MTT assays. Apoptotic markers were tested by the AO/PI double staining assay and DNA fragmentation test. Flow cytometry was conducted to measure cell cycle distribution, while the p53 and caspase-8 pathways were tested via immunofluorescence assay. Results demonstrated that the cytotoxic effect of the Pt(II)-thiocarbohydrazone complexes against Caov-3 and HT-29 cells was highly significant, and this effect triggered the activation of the p53 and caspase-8 pathways. Besides, apoptosis stimulated by the Pt(II)-thiocarbohydrazone complex was associated with cell cycle arrest at the G0/G1 phase. These findings suggest that the target complex inhibited the proliferation of Caov-3 and HT-29 cells, resulting in the arrest of the cell cycle and induction of apoptosis via the stimulation of the p53 and caspase-8 pathways. The present data suggests that the Pt(II)-thiocarbohydrazone complex could also be a promising chemotherapeutic agent for other types of cancer cells.

scholarly journals The role of estrogen in the survival of ovarian tumors—A study of the human ovarian adenocarcinoma cell lines OC-117-VGH and OVCAR3

2013 ◽  
Vol 76 (2) ◽  
pp. 63-70 ◽  
Author(s):  
Kuan-Chong Chao ◽  
Peng-Hui Wang ◽  
Chi-Ching Chang ◽  
Ming-Shyen Yen ◽  
Chin-Wen Chi
Keyword(s):  
Cell Lines ◽  
Ovarian Tumors ◽  
Ovarian Adenocarcinoma ◽  
Adenocarcinoma Cell

scholarly journals Mangiferin induces apoptosis in human ovarian adenocarcinoma OVCAR3 cells via the regulation of Notch3

2017 ◽  
Vol 38 (3) ◽  
pp. 1431-1441 ◽  
Author(s):  
Bingyu Zou ◽  
Hailian Wang ◽  
Yilong Liu ◽  
Ping Qi ◽  
Tiantian Lei ◽  
...  
Keyword(s):  
Ovarian Adenocarcinoma

nm23 expression in malignant ascitic effusions of serous ovarian adenocarcinoma

2001 ◽  
Author(s):  
Gianni Simone ◽  
Gaetano Falco ◽  
Maria Caponio ◽  
Carlo Campobasso ◽  
Massimo De Frenza ◽  
...  
Keyword(s):  
Ovarian Adenocarcinoma ◽  
Serous Ovarian Adenocarcinoma

Stromal osseous metaplasia in a low-grade ovarian adenocarcinoma

2005 ◽  
Vol 99 (1) ◽  
pp. 222-224 ◽  
Author(s):  
P. Mukonoweshuro ◽  
A. Oriowolo
Keyword(s):  
Osseous Metaplasia ◽  
Low Grade ◽  
Ovarian Adenocarcinoma

Cure of mice with advanced ovarian adenocarcinoma CaO1 by the serum blood proteins

2021 ◽  
Vol 172 (8) ◽  
pp. 223-227
Author(s):  
F. V. Donenko ◽  
◽  
S. M. Sitdikova ◽  
Yu. I. Dolzhikova ◽  
Yu. S. Lebedin ◽  
...  
Keyword(s):  
Blood Proteins ◽  
Ovarian Adenocarcinoma

scholarly journals P14.123 Neurological complications related to checkpoints inhibitors

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii97-iii98
Author(s):  
I Esparragosa ◽  
R Valenti-Azcarate ◽  
D Moreno-Ajona ◽  
J Gallego Perez de Larraya
Keyword(s):  
Cerebrospinal Fluid ◽  
Checkpoint Inhibitors ◽  
Early Recognition ◽  
Oral Prednisone ◽  
Fatal Outcome ◽  
Case Series ◽  
Neurological Complications ◽  
Ovarian Adenocarcinoma ◽  
Inflammatory Myositis ◽  
Oncological Treatment

Abstract BACKGROUND Currently, immunotherapy is part of the therapeutic arsenal for oncological treatment. Indeed, the need for new medications has led to the development of immune checkpoint inhibitors. Despite favourable oncological outcomes, these treatments have been associated with immune-related adverse events. Although infrequent, neurological toxicities have been reported. Early recognition is crucial for improvement of functional outcome and requires a multidisciplinary approach. OBJECTIVE To describe a case series of patients with neurological complications related to checkpoint inhibitors. PATIENTS AND METHODS We identified six oncological patients who presented immunomediated neurological complications, derived from the use of checkpoints inhibitors. Five cases were men. Ages ranged from 58 to 73 years. Nivolumab, alone or combined, was the most commonly associated drug (4/6). Underlying diseases included lung carcinoma (2/6), melanoma (2/6), renal carcinoma (1/6) and ovarian adenocarcinoma (1/6). An acute demyelinating sensory-motor polyneuropathy and an acute axonal sensory polyneuropathy were documented in two and one case, respectively. In these, the cerebrospinal fluid analysis revealed albuminocytologic dissociation. All three cases improved after treatment with intravenous immunoglobulins (0.4 g/Kg a day for five days). The latter and another case were diagnosed of aseptic meningitis after cerebrospinal fluid lymphocytic pleocytosis was found. High fever was also associated with lower extremities areflexia, weakness and ataxia. Methylprednisolone (1g/day for five days) was administered. One case of necrotizing inflammatory myositis with high levels of creatine kinasa, confirmed by muscular biopsy, involving cervical weakness and ptosis, was effectively treated with Methylprednisolone (1g/day for five days) follow by oral prednisone tapering. An anti-Yo related pancerebellar syndrome was the only case with a fatal outcome despite treatment. CONCLUSION The increasingly frequent use of immunotherapy in the treatment of cancer may lead to an increase in neurological complications. These include a broad spectrum of syndromes with peripheral nervous system predominantly susceptible. Early identification of these and appropriate management of drug-related toxicity are required. Immune-modulating therapies are particularly beneficial.

scholarly journals Effects of Sex Steroids and Growth Factors on Invasive Activity and 5′-Deoxy-5-fluorouridine Sensitivity in Ovarian Adenocarcinoma OMC-3 Cells

1998 ◽  
Vol 89 (12) ◽  
pp. 1334-1342 ◽  
Author(s):  
Masatsugu Ueda ◽  
Hideji Fujii ◽  
Keiko Yoshizawa ◽  
Koji Kumagai ◽  
Ken Ueki ◽  
...  
Keyword(s):  
Growth Factors ◽  
Sex Steroids ◽  
Ovarian Adenocarcinoma
Sign in / Sign up

Export Citation Format

Share Document